Answers are grounded in this paper and cite their sources.
High‑altitude pulmonary edema (HAPE) is a severe form of non‑cardiogenic acute lung injury triggered by hypobaric hypoxia, classically attributed to dysregulated pulmonary vasoconstriction and barrier failure, with inflammation and oxidative stress acting as amplifiers of this injury. Baicalin (BA), a flavonoid from Scutellaria baicalensis, has recognized antioxidant and anti‑inflammatory activities, but its effects in HAPE are not fully understood. BA in a hypobaric hypoxia‑induced HAPE was assessed in a mouse model and in a CoCl2‑induced hypoxic macrophage model. Lung edema/injury, redox status and inflammation were analyzed using histology and biochemical assays, immunofluorescence, transmission electron microscopy, western blotting and reverse transcription‑quantitative PCR. Pathway candidates were explored by network pharmacology and molecular docking and then verified experimentally. BA pretreatment reduced pulmonary edema and tissue damage, lowered reactive oxygen species and decreased proinflammatory cytokine production. BA treatment was associated with increased PI3K/Akt phosphorylation in vivo and in vitro and concurrently inhibited NOD‑like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation, limiting caspase‑1 activation, gasdermin D cleavage and IL‑1β/IL‑18 maturation and release. Blocking PI3K largely reversed these benefits, supporting a PI3K/Akt‑dependent mechanism. Overall, BA protects against hypobaric hypoxia‑induced lung injury in association with increased PI3K/Akt phosphorylation and suppresses oxidative stress‑linked NLRP3 inflammasome‑associated pyroptotic signaling, highlighting BA as a potential prophylactic agent for the prevention of high‑altitude‑related lung injury.
No takes yet. Share an insight, caveat, or question.
chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: